HMMJ-U:CA:TSX-Horizons Marijuana Life Sciences Index ETF (USD)

ETF | Others |

Last Closing

CAD 7.5

Change

0.00 (0.00)%

Market Cap

CAD 0.09B

Volume

300.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

N/A

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

+0.01 (+0.02%)

CAD 4.87B
PHYS-U:CA Sprott Physical Gold Trust

+0.26 (+1.45%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.26 (+0.40%)

CAD 4.54B
HXT-U:CA Horizons S&P/TSX 60 Index ETF

N/A

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

+0.41 (+1.90%)

CAD 3.78B
XEQT:CA iShares Core Equity Portfolio

+0.08 (+0.26%)

CAD 3.29B
PSLV-U:CA Sprott Physical Silver Trust

+0.16 (+1.72%)

CAD 3.29B
IGAF:CA IA Clarington Loomis Global Al..

N/A

CAD 3.23B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.04 (-0.18%)

CAD 2.78B

ETFs Containing HMMJ-U:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.30% 75% C 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.30% 74% C 64% D
Trailing 12 Months  
Capital Gain 5.78% 53% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.78% 52% F 51% F
Trailing 5 Years  
Capital Gain -52.38% 2% F 11% F
Dividend Return 1.27% 63% D 7% C-
Total Return -51.11% 2% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 14.15% 97% N/A 83% B
Dividend Return 14.20% 97% N/A 81% B-
Total Return 0.05% 55% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 65.72% 2% F 12% F
Risk Adjusted Return 21.61% 62% D 50% F
Market Capitalization 0.09B 64% D 35% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.